Patients with gastroesophageal reflux disease and Barrett’s esophagus can be a management challenge for the treating physician or surgeon. The goals of therapy include relief of reflux symptoms, induction of…
Barrett’s esophagus (BE) is present in up to 5.6% of the US population and is the precursor lesion for esophageal adenocarcinoma. Surveillance endoscopy is the primary management approach for BE….
Approximately 10% to 15% of the chronic gastroesophageal reflux disease population is at risk for the development of Barrett’s esophagus, particularly in the setting of other risk factors, including male…
Proton pump inhibitors (PPIs) may protect against carcinogenesis in Barrett’s esophagus because they eliminate the chronic esophageal inflammation of reflux esophagitis, and because they decrease esophageal exposure to acid, which…
Barrett’s esophagus is the only identifiable premalignant condition for esophageal adenocarcinoma. Endoscopic eradication therapy (EET) has revolutionized the management of Barrett’s-related dysplasia and intramucosal cancer. The primary goal of EET…
Esophageal adenocarcinoma (EAC) has increased dramatically in the past 3 decades, making its precursor lesion Barrett’s esophagus (BE) an important clinical problem. Effective interventions are available, but overall outcomes remain…
A major paradigm shift has occurred in the management of dysplastic Barrett’s esophagus (BE) and early esophageal carcinoma. Endoscopic therapy has now emerged as the standard of care for this…
Barrett’s esophagus (BE) is more common in developed countries. Endoscopic therapy is an effective treatment method in management of dysplastic BE. Ablation by thermal energy, freezing, or photochemical injury completely…
The prevalence of esophageal adenocarcinoma is increasing dramatically. Barrett’s esophagus remains the most well-established risk factor for the development of esophageal adenocarcinoma. There are multiple clinical, endoscopic, and pathologic factors…
There is substantial interest in identifying patients with premalignant conditions such as Barrett’s esophagus (BE), to improve outcomes of subjects with esophageal adenocarcinoma. However, there is limited consensus on the…
